The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP).

Original title: “Government Owned Invention Available for License: Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof”

clonal expansion and phenotypic alterations of tcr v 3 t cells in juvenile onset recurrent respiratory papillomatosis implications for tumor associated immunity and chemokine mediated t cell trafficking

Original title: “Clonal expansion and phenotypic alterations of TCR Vβ3(+) T cells in juvenile-onset recurrent respiratory papillomatosis: implications for tumor-associated immunity and chemokine-mediated T-cell trafficking.”

development of a novel prognostic assessment tool for recurrent respiratory papillomatosis

Original title: “Development of a novel prognostic assessment tool for recurrent respiratory papillomatosis.”

patient perspective of living with recurrent respiratory papillomatosis

Original title: “The Patient Perspective of Living With Recurrent Respiratory Papillomatosis.”